About Us

We pride ourselves on delivering customised solutions to meet the unique needs of each of our clients. Our team works closely with our clients to ensure that they receive the support they need when they need it to succeed in their clinical research efforts. Whether you are a small startup or a large pharmaceutical company, we have the expertise and resources to help you deliver your project on time and within budget. We are committed to delivering quality services and supporting our partners every step of the way.

Mission

At SAFIRA, we specialise in providing expert services to support our clients in their mission to bring safe and effective treatments to patients worldwide. Our team of dedicated professionals has years of experience in the clinical research industry and a deep understanding of the complex regulatory landscape. We offer a wide range of services, including eClinical technology consulting, User Acceptance Testing (UAT) for eCOA, eConsent, RTSM, and EDC, Data Monitoring, License Management, eCOA product support, change management and Training (Online and face2face).

Gauri Nagrani

Gauri Nagrani, founding partner of Safira, brings more than 15+ years of experience within the clinical research field, where she has held leadership roles within the data management and eClinical groups.

Gauri pursued her graduate degrees in Biochemistry, Pharmacology and Pharmaceutical Research & Development in Canada at McGill University. She started her professional career by supporting research, operations and programming at Chiltern and AstraZeneca.

After some mergers and acquisitions she managed Covance´s FSP team for eCOA services until she started her own consultancy in 2018.

Her work and enthusiasm was recognized in 2023 when she was listed in PharmaVoice100.

Willie Muehlhausen

Willie Muehlhausen is a founding Partner of SAFIRA. He has more than 25 years of experience in global technology companies supporting clinical trials with a focus in patient-facing technologies.

Before he co-founded SAFIRA in 2021, Willie Muehlhausen worked as a technology consultant supporting eCOA companies and sponsors. He held the position of VP Innovation at ICON from October 2012 through July 2018 where he led several initiatives to prepare ICON for Decentralized Clinical Trials. Prior to this role he was ICON´s Executive Director eCOA and established a team of experts who managed all ICON eCOA projects. From September 2006 through October 2011 Willie Muehlhausen led the ePRO development for VIASYS Healthcare, which was ultimately acquired by ERT (now CLARIO) as Product Owner and was elected to lead the ePRO Consortium as the inaugural Vice Director Industry.

Throughout his career, he initiated a multitude of research projects on eCOA topics to improve the overall knowledge across the industry and he co-authored a leading ePRO Implementation Handbook, which is now available in a 2nd edition.

His research papers have been widely referenced and in 2022 was referenced in the “FDA Guideline for Patient-Focused Drug Development Part 3”.

Mr Muehlhausen began his career as Veterinary Surgeon after he graduated from the Free University in Berlin, Germany in 1996. In 2015 he was recognized as an Innovation leader by PharmaVoice 100 and as Top20 Innovator CenterWatch in 2018.